These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12624245)

  • 1. HIV. Escape artist par excellence.
    Cohen J
    Science; 2003 Mar; 299(5612):1505-8. PubMed ID: 12624245
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 3. Virology. HIV may shed some protection as it jumps to new hosts.
    Cohen J
    Science; 2004 Mar; 303(5666):1956. PubMed ID: 15044774
    [No Abstract]   [Full Text] [Related]  

  • 4. Virology. Moving forward in HIV vaccine development.
    Letvin NL
    Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
    [No Abstract]   [Full Text] [Related]  

  • 5. RV144: old vs. new.
    Weiner DB
    Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
    [No Abstract]   [Full Text] [Related]  

  • 6. The RV144 Thai HIV vaccine trial.
    Plotkin SA
    Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
    [No Abstract]   [Full Text] [Related]  

  • 7. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost immunization strategies against HIV.
    Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958
    [No Abstract]   [Full Text] [Related]  

  • 9. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV vaccines. Viral envelope fails to deliver?
    Bolognesi DP; Matthews TJ
    Nature; 1998 Feb; 391(6668):638-9. PubMed ID: 9490406
    [No Abstract]   [Full Text] [Related]  

  • 12. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody neutralization of human immunodeficiency virus type 1 (HIV-1).
    Schønning K
    APMIS Suppl; 2003; (111):1-42. PubMed ID: 12739253
    [No Abstract]   [Full Text] [Related]  

  • 14. AIDS vaccines: back to 'plan A'.
    Check E
    Nature; 2003 Jun; 423(6943):912-4. PubMed ID: 12827164
    [No Abstract]   [Full Text] [Related]  

  • 15. Fusion inhibitors, T-20; chemokine variants; tat and interferon antibodies: Gallo describes three new treatment approaches.
    James JS
    AIDS Treat News; 1998 Jul; (No 299):4-5. PubMed ID: 11365600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving on nature: focusing the immune response on the V3 loop.
    Zolla-Pazner S
    Hum Antibodies; 2005; 14(3-4):69-72. PubMed ID: 16720976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV/AIDS: allied responses.
    Mascola JR
    Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
    [No Abstract]   [Full Text] [Related]  

  • 18. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level.
    Bunnik EM; Euler Z; Welkers MR; Boeser-Nunnink BD; Grijsen ML; Prins JM; Schuitemaker H
    Nat Med; 2010 Sep; 16(9):995-7. PubMed ID: 20802498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
    Pitisuttithum P; Nitayaphan S; Thongcharoen P; Khamboonruang C; Kim J; de Souza M; Chuenchitra T; Garner RP; Thapinta D; Polonis V; Ratto-Kim S; Chanbancherd P; Chiu J; Birx DL; Duliege AM; McNeil JG; Brown AE;
    J Infect Dis; 2003 Jul; 188(2):219-27. PubMed ID: 12854076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.